Investors

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials

14 December 2017, Sophia Antipolis, France

Press release – For immediate release – 5:45pm CET

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials

  • New platform enables high quality, accurate and predictive data for critical imaging endpoints

Median Technologies, the industry-leading Imaging Phenomics Company® (Paris:ALMDT) announced the launch of iSee® – a comprehensive technology platform that enables rapid analysis and better management of medical images in clinical trials. iSee® strengthens the imaging clinical research organization (iCRO) offering by helping biopharmaceutical companies reduce project start-up time and improve user workflows. The scalable and configurable iSee® platform ensures high quality, accurate and predictive data for successful imaging endpoints.

This first release of iSee® includes all the image analysis features and the proprietary algorithms library integrated into its predecessor, Lesion Management Solution (LMS), Median Technologies’ legacy, groundbreaking imaging software platform. iSee® will integrate additional features to surpass the demands of drug development in the twenty-first century by helping to meet the rising challenges of medical image management, with specific emphasis on multimodal medical image fusion requiring cutting-edge image viewers and specialized criteria to evaluate disease response.

“With the release of iSee®, we continue our commitment to providing the best imaging support to our biopharmaceutical customers in conducting their clinical trials. Helping our clients achieve their goals is a core value at Median Technologies. We strive to meet their expectations through innovation, imaging expertise, superior services and quality solutions,” highlights Jeanne Hecht, COO of Median Technologies. “Through the launch of iSee®, we remain committed to delivering innovative technologies to the biopharmaceutical industry – supporting them in their quest to bring new therapies to the market for patients who need them,” Hecht adds.

Cookies help us deliver our services. By using our services, you agree to our use of cookies.